Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer

BACKGROUND: KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC; NCT01702571). We report the final analysis of cohort 2 (Asia) within the context of published cohort 1 (Global) find...

Descripción completa

Detalles Bibliográficos
Autores principales: Wuerstlein, R., Ellis, P., Montemurro, F., Antón Torres, A., Delaloge, S., Zhang, Q., Wang, X., Wang, S., Shao, Z., Li, H., Rachman, A., Vongsaisuwon, M., Liu, H., Fear, S., Peña-Murillo, C., Barrios, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588895/
https://www.ncbi.nlm.nih.gov/pubmed/36084395
http://dx.doi.org/10.1016/j.esmoop.2022.100561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588895/
https://www.ncbi.nlm.nih.gov/pubmed/36084395
http://dx.doi.org/10.1016/j.esmoop.2022.100561

Ejemplares similares